Potential reduction in neural tube defects associated with use of Metafolin-fortified oral contraceptives in the United States

American Journal of Obstetrics and Gynecology

Volumn 205, Issue 5, 2011, Pages 460.e1-460.e8

  Taylor, Thomas N ^a   Farkouh, Raymond A ^b   Graham, Jonathan B ^b   Colligs, Antje ^c   Lindemann, Marion ^c   Lynen, Richard ^d   Candrilli, Sean D ^b  

^a WAYNE STATE UNIVERSITY   (United States)

^b RTI HEALTH SOLUTIONS   (United States)

^c BAYER PHARMA AG   (Germany)

^d BAYER CORPORATION   (United States)

Author keywords

epidemiology; folate; Metafolin; neural tube defects; oral contraceptive

Indexed keywords

FOLIC ACID; FOLIC ACID DERIVATIVE; METAFOLIN FORTIFIED ORAL CONTRACEPTIVE; ORAL CONTRACEPTIVE AGENT; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; ARTICLE; ERYTHROCYTE; FEMALE; FOLIC ACID BLOOD LEVEL; HEALTH SURVEY; HUMAN; MAJOR CLINICAL STUDY; NEURAL TUBE DEFECT; POPULATION RESEARCH; PREDICTION; PREGNANCY; PRIORITY JOURNAL; RISK FACTOR; SENSITIVITY ANALYSIS; UNITED STATES;

EID: 80255129290     PISSN: 00029378     EISSN: 10976868     Source Type: Journal    
DOI: 10.1016/j.ajog.2011.06.048     Document Type: Article

References (33)

1. R.M. Pitkin Folate and neural tube defects Am J Clin Nutr 85 2007 285S 288S (Pubitemid 46067650)
2. J.D. Cragan, H.E. Roberts, and L.D. Edmonds Surveillance for anencephaly and spina bifida and the impact of prenatal diagnosis: United States, 1985-1994 MMWR CDC Surveill Summ 44 1995 1 13
3. L.D. Botto, C.A. Moore, M.J. Khoury, and J.D. Erickson Neural-tube defects N Engl J Med 341 1999 1509 1519 (Pubitemid 29526355)
4. L. Ouyang, S.D. Grosse, B.S. Armour, and N.J. Waitzman Health care expenditures of children and adults with spina bifida in a privately insured US population Birth Defects Res A Clin Mol Teratol 79 2007 552 558 (Pubitemid 47068191)
5. Centers for Disease Control and Prevention Recommendations for the use of folic acid to reduce the number of cases of spina bifida and other neural tube defects MMWR Morb Mortal Wkly Rep 41 RR-14 1992
6. L.E. Daly, P.N. Kirke, and A. Molloy Folate levels and neural tube defects Implications for prevention JAMA 274 1995 1698 1702
7. B. Burke, K.L. Daniel, and A. Latimer Preventing neural tube birth defects: a prevention model and resource guide 2009 Centers for Disease Control and Prevention Atlanta, GA
8. US Preventive Services Task Force Folic acid for the prevention of neural tube defects: US Preventive Services Task Force Recommendation Statement Ann Intern Med 150 2009 626 631
9. Q.H. Yang, H.K. Carter, and J. Mulinare Race-ethnicity differences in folic acid intake in women of childbearing age in the United States after folic acid fortification: findings from the National Health and Nutrition Examination Survey, 2001-2002 Am J Clin Nutr 85 2007 1409 1416 (Pubitemid 46740486)
10. Centers for Disease Control and Prevention Use of supplements containing folic acid among women of childbearing ageUnited States, 2007 MMWR Morb Mortal Wkly Rep 57 2008 5 8
11. Centers for Disease Control and Prevention Spina bifida and anencephaly before and after folic acid mandateUnited States, 1995-1996 and 1999-2000 MMWR Morb Mortal Wkly Rep 53 2004 362 365
12. L.B. Finer, and S.K. Henshaw Disparities in rates of unintended pregnancy in the United States, 1994 and 2001 Perspect Sex Reprod Health 38 2006 90 96 (Pubitemid 43882311)
13. A. Chandra, G.M. Martinez, W.D. Mosher, J.C. Abma, and J. Jones Fertility, family planning, and reproductive health of US women: data from the 2002 National Survey of Family Growth National Center for Health Statistics Vital Health Stat 23 2005 1 160
14. M. Cronin, I. Schellschmidt, and J. Dinger Rate of pregnancy following use of drospirenone- and other progestin-containing oral contraceptives Obstet Gynecol 114 2009 616 622
15. S.K. Henshaw Unintended pregnancy in the United States Fam Plann Perspect 30 1998 24 29 46
16. J. Trussell Contraceptive failure in the United States Contraception 70 2004 89 96 (Pubitemid 38993483)
17. J. Trussell, and B. Vaughan Contraceptive failure, method-related discontinuation and resumption of use: results from the 1995 National Survey of Family Growth Fam Plann Perspect 31 1999 64 72 93
18. US Food and Drug Administration, Center for Drug Evaluation and Research, Advisory Committee for Reproductive Health Drugs Summary minutes of the December 15, 2003, meeting http://www.fda.gov/ohrms/dockets/ac/03/minutes/ 4002M1-Final.htm Accessed June 7, 2010
19. C.R. Raven Fortifying oral contraceptives with folic acid How this concept could benefit women of reproductive age AWHONN Lifelines 8 2004 12 13
20. K. Diefenbach, D. Trummer, F. Ebert, M. Lissy, B. Rohde, and H. Blode Changes in folate levels following a 24-week co-administration of Yasmin and levomefolate calcium 0.451 mg or folic acid 400 mcg Eur J Contracept Reprod Health Care 15 Suppl 1 2010 158 159
21. K. Diefenbach, D. Trummer, F. Ebert, M. Lissy, B. Rohde, and H. Blode Changes in folate levels following cessation of Yasmin and levomefolate calcium 0.451 mg or folic acid 400 mcg co-administration Eur J Contracept Reprod Health Care 15 Suppl 1 2010 157 158
22. J. Marr, C. Sampson-Landers, K. Diefenbach, D. Trummer, S. Bart, and H. Blode Folate and homocysteine levels after 24 weeks administration of YAZ + levomefolate calcium 0.451 mg Eur J Contracept Reprod Health Care 15 Suppl 1 2010 159
23. Food and Drug Administration Beyaz Highlights of Prescribing Information http://www.accessdata.fda.gov/drugsatfda-docs/label/2010/022532s000lbl.pdf 2010 Accessed April 7, 2011
24. M.A. McDowell, D.A. Lacher, and C.M. Pfeiffer Blood folate levels: the latest NHANES results NCHS Data Brief 2008 1 8
25. W.D. Mosher, G.M. Martinez, A. Chandra, J.C. Abma, and S.J. Willson Use of contraception and use of family planning services in the United States, 1982-2002 Advance data from Vital and Health Statistics; No. 350 2004 National Center for Health Statistics Hyattsville, MD
26. US Census Bureau National population projections; II. Detailed files NP-D1-A: projections of the resident population by age, sex, race, and Hispanic origin: 1999 to 2100 http://www.census.gov/population/projections/nation/detail/ d2001-10.pdf 2000 Accessed Jan. 21, 2008
27. E. Colli, D. Tong, R. Penhallegon, and F. Parazzini Reasons for contraceptive discontinuation in women 20-39 years old in New Zealand Contraception 59 1999 227 231 (Pubitemid 29361477)
28. M.J. Rosenberg, and M.S. Waugh Oral contraceptive discontinuation: a prospective evaluation of frequency and reasons Am J Obstet Gynecol 179 1998 577 582 (Pubitemid 28447229)
29. Centers for Disease Control and Prevention, National Center for Health Statistics National Health and Nutrition Examination Survey data, 2005-2006 http://www.cdc.gov/nchs/about/major/nhanes/nhanes2005-2006/nhanes05-06.htm 2008 Accessed Dec. 1, 2008
30. Z. Fazili, C.M. Pfeiffer, and M. Zhang Comparison of serum folate species analyzed by LCMS/MS with total folate measured by microbiologic assay and bio-rad radioassay Clin Chem 53 2007 781 785
31. R.K. Jones, M.R.S. Zolna, S.K. Henshaw, and L.B. Finer Abortion in the United States: incidence and access to services, 2005 Perspect Sex Reprod Health 40 2008 6 16
32. D.L. Hoyert Medical and life-style risk factors affecting fetal mortality, 1989-90 National Center for Health Statistics Vital Health Stat 20 1996 1 32
33. J. Lumley, L. Watson, M. Watson, and C. Bower Modelling the potential impact of population-wide periconceptional folate/multivitamin supplementation on multiple births BJOG 108 2001 937 942 (Pubitemid 32778588)